Curasight
2.06
DKK
-10.82 %
Less than 1K followers
CURAS
Spotlight Stock Market
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreMarket cap
94.48M DKK
Turnover
1.04M DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 07.05.2025
Financial calendar
28.8
2025
Interim report Q2'25
27.11
2025
Interim report Q3'25
All
Research
Webcasts
Press releases
ShowingAll content types
Curasight: The exercise period commences for warrants of series TO3 on 4 June 2025
Dagens aktienyheder 02/06: Impero - Compliance. Simplified. MapsPeople, AUDIENTES, Pharma Equity Group A/S (PEG), GreenMobility A/S og Curasight
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Curasight: Gennemfører en rettet emission af aktier til garanter i forbindelse med fortegningsemissionen
Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue
Curasight: Completed registration of rights issue
Resolutions of the Annual General Meeting 2025 of Curasight A/S
Dagens aktienyheder 21/05: MapsPeople, Curasight, Vestjysk Bank, Spar Nord og Scandinavian Medical Solutions
Curasight: Endeligt udfald af kapitalforhøjelsen
Curasight announces outcome in rights issue
Subscription of new shares in the Right Issue 2025 exercised by Curasight management
Dagens aktienyheder 14/05: Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight
Curasight - Video med opfølgning på kapitalforhøjelsen DKK 100 mio.
Curasight: Notice of Annual General Meeting 2025
Curasight – Opfølgning på fortegningsemission
Last day of the subscription period in Curasight's rights issue of shares
Dagens aktienyheder 07/05: Sampo plc, Agillic, GomSpace og Curasight
Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer
